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Objective: To determine if a concurrent diagnosis of diabetes mellitus is associated with
worse outcomes in advanced prostate cancer (PC). The effect diabetes may have on the
progression of advanced PC is poorly understood.
Methods: Data on 148 advanced PC patients (35 with concurrent diabetes) were
collected from an institutional database to obtain diabetic status, data on treatment types
and durations, and prostate-specific antigen (PSA) values before, during, and after treat-
ment. Time to castration resistance following the onset of androgen deprivation therapy
(ADT) and overall survival (OS) in patients with and without diabetes were compared using
univariate Cox regression analyses as the primary endpoints. Differences in PSA response
to treatments were compared using chi-squared tests as a secondary endpoint.
Results:With amedian follow-up of 29months, time to castration resistance did not differ
significantly between patients with and without diabetes who underwent ADT. However,
in a subset of patients who received ADT without radiographic evidence of metastases
(N=47), those with diabetes progressed to castration-resistant diseasemore quickly than
those without DM (hazard ratio for progression with diabetes=4.58; 95%CI: 1.92–10.94;
p=0.0006). Also, a lower percentage of patients undergoing ADT with diabetes had PSA
declines of at least 50% (p=0.17) and reached a nadir PSA <0.2 ng/mL (p=0.06). OS
did not differ based on diabetic status. No differences were seen in response to first-line
therapy for castration-resistant prostate cancer.
Conclusion: Diabetes mellitus may have a detrimental effect on progression of advanced
PC, particularly in those patients without radiographic evidence of metastases. Further
study is necessary to fully elucidate the effect of diabetes on PC outcomes.
Keywords: androgen deprivation therapy, diabetes mellitus, time to castration-resistant prostate cancer, insulin
resistance and cancer, hormone-sensitive prostate cancer
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Introduction
Previous studies have suggested intriguing associations between
prostate cancer (PC) and diabetes mellitus. Examples of such
associations include the tendency of PC treatments to induce or
exacerbate metabolic syndrome and type 2 diabetes in patients
undergoing androgen deprivation therapy (ADT) for advanced
PC (1–5). Additionally, some have suggested that diabetes may
be a protective factor against developing PC (6–10). Studies have
also shown that diabetes and worse glycemic control are associ-
ated with higher Gleason scores at initial biopsy and increased
mortality (11–14).
The metabolic syndrome and the early stages of type 2 diabetes
are frequently associated with insulin resistance in metabolic
tissues and a compensatory endogenous hyperinsulinemia
in order to maintain normal circulating glucose levels (15).
Chronic endogenous hyperinsulinemia has been proposed to be a
contributing factor to the progression of PC. Ma et al. found that
higher concentrations of C-peptide, a serum marker that reflects
endogenous insulin release, were associated with a higher risk of
PC mortality (16). Insulin and its binding to the insulin receptor
have been shown to activate mitogenic pathways in PC cell lines
(17). It has also been demonstrated that insulin increases de novo
steroidogenesis in PC cells, and that there are increased levels
of insulin receptors on human PC cells compared to normal
prostatic epithelium, suggesting that insulin is a mediator of PC
growth and function (18, 19). But while the current literature
analyzes the effects of diabetes on PC, it mostly reflects outcomes
in local PC or does not specify disease state at all (20–22).
The effect that diabetes might have on PC progression, espe-
cially in advanced disease, is not well studied. In a comprehensive
review analyzing the effects of diabetes on PC, Snyder et al.
noted that one of their more important findings was the lack of
research on the subject (23). The gap in the literature is partic-
ularly troublesome when considering the epidemiologic overlap
between these two common diseases. According to the American
Diabetes Association, 27% of the US population over 65 years
of age has diabetes, the majority of whom have type 2 diabetes,
while data from the SEER PC database indicate that 36.3% of
new PC diagnoses are made in men between the ages of 65
and 74. Additionally, a European study found that 32% of their
patients with castration-resistant prostate cancer (CRPC) also
had a concurrent diagnosis of diabetes (24). This has important
clinical implications, considering the findings that insulin can be a
growth factor and can increase de novo steroidogenesis, and could
therefore provide a mechanism for castration resistance. CRPC
carries a poor prognosis, withmedian survivals of patients ranging
from 9 to 30months (25).
In this retrospective study, we examine the correlation between
a diagnosis of diabetes mellitus and differences in overall survival
(OS), time to castration resistance, and prostate-specific antigen
(PSA) response to ADT in men with advanced PC.
Materials and Methods
Data Collection
Data for this retrospective study were collected from the Icahn
School of Medicine at Mount Sinai’s Genitourinary Cancer
Biorepository. The study was approved by the Mount Sinai Insti-
tutional Review Board (GCO# 10-1180). This research database
contains records of date of birth, date of death, race, last known
disease status, last known treatment status, start and end dates for
treatments, clinical indications for treatments, extent of disease
at initial diagnosis, GS at initial biopsy, PSA values and their
corresponding dates, and major comorbidities. The database has
patient data collected retrospectively to 1991 and is continually
updated to ensure quality control.
Case Selection
In screening subjects for this study, we only considered patients
in the GU Cancer Biorepository who had provided consent to
research projects. Preliminary inclusion was based on treatment
and disease status; only patients who had begun to receive ADT
for non-adjuvant or non-neoadjuvant treatment in the setting
of biochemical recurrence or metastatic disease or who received
therapy for CRPC were eligible. If a patient progressed from
hormone-sensitive PC to CRPC, then the patient was grouped
into a study of each respective disease state. Patients with small
cell carcinomas of the prostate were not included. A diagnosis
of diabetes was determined by the patient history reported either
in the database or in their electronic medical record at the Icahn
School ofMedicine atMount Sinai. If a patient developed diabetes
after the start of their treatment, they were included in the diabetic
cohort. A total of 148 patients were enrolled in this study based
on the above criteria, many of whom were included in both the
studies on hormone-sensitive PC and CRPC (Figure 1). For cer-
tain outcome measurements, more data elements were required,
and patients were excluded from these measurements if necessary
data elements were unavailable. The necessary data elements for
each test are included in the results section.
Outcomes Measured and Statistical Analysis
In the hormone-sensitive cohort, primary outcomes measured
were time to CRPC and OS following the onset of ADT. In the
cohort of patients with CRPC, the primary outcome was OS
following the onset of castration resistance. Secondary outcomes
were percentage of patients with a PSA response to ADT or first-
line therapy for CRPC as measured by 50% reduction, and
percentage of patients responding with a nadir PSA <0.2 ng/mL
following ADT.
Both time to CRPC and OS were compared between patients
with and without diabetes using Kaplan–Meier survival plots and
Cox proportional hazard ratios. The difference in the percentage
of patients who responded to their treatment based on the per-
centage of PSA reduction and nadir PSA<0.2 ng/mL between the
groups of patients with and without diabetes was compared using
the χ2 test. All statistics including statistical significance values
were computed using Statistical Package for the Social Sciences
(SPSS) (26).
Definition of Castration Resistance
Time to CRPC was calculated as the time from the onset of non-
adjuvant ADT to the date of castration resistance. The following
four definitions were used to determine castration resistance, the
earliest of which to occur was used as the date of progression: (1)
two rises in PSA at least 1 week apart while on castration therapy
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FIGURE 1 | Study design: 127 hormone-sensitive patients in the
database were treated with ADT for advanced PC. Of those patients, 47
began treatment without radiographic evidence of metastases, 87
hormone-sensitive patients progressed to CRPC, and an additional 21 patients
were treated for CRPC whose clinical data from their hormone-sensitive state
was not available, totaling 108 patients with CRPC in the study. In all subset of
patients, outcomes were compared between patients with diabetes and those
without diabetes.
or after bilateral orchiectomy signified CRPC, and the date of
progression used was the date of the first rise. The first rise in
PSA must have been at least 0.02 ng/mL greater than the previous
PSA value, and the second rise must have been greater than the
first rise in PSA, (2) treatment with an androgen receptor analog
such as bicalutamide or enzalutamide at least 2 weeks after the
start of castration therapy, or switching analogs at least 2 weeks
after the start of castration therapy if the initial therapy was com-
bined androgen blockade, (3) treatment with an adrenal steroid
enzyme inhibitor (ketoconazole, abiraterone), sipuleucel-T, or
non-adjuvant chemotherapy (docetaxel, cabazitaxel), (4) presence
of a doctor’s note in the patient’s medical record indicating the
patient had CRPC.
Definition of PSA Response
In order to be eligible for analysis of PSA response, patients had to
have a baseline PSA measurement within 1 year prior to the onset
of treatment type in addition to at least one PSA measurement
after the onset of the first treatment but before the onset of
additional therapy, the lowest of which was used to calculate the
percentage reduction in PSA in response to the given therapy. To
be eligible for the analysis of nadir PSA following ADT, patients
needed to have PSA values after the onset of ADT and before they
progressed to CRPC.
Results
Time to CRPC
The characteristics of eligible patients are detailed in Table 1.
Of the 148 patients in the database with advanced PC, 127
underwent ADT for biochemically recurrent or metastatic PC;
of these, 30 patients had concurrent diabetes. Median follow-up
was 29months (range 0–154months). In this cohort, there was no
observed difference in time to CRPC between patients with and
TABLE 1 | Characteristics of eligible patients.
Characteristic Without DM With DM
N= 113 N= 35
Age at start of therapy (years)
Median 68 73
Interquartile range 63-75 66-78
Race (%)
White 70 (61.9) 20 (57.1)
Black 23 (20.4) 7 (20.0)
Hispanic 9 (8.0) 4 (11.5)
Other 8 (7.1) 2 (5.7)
Not reported 3 (2.6) 2 (5.7)
Gleason score (%)
7 37 (32.7) 10 (28.6)
8–10 56 (49.6) 19 (54.3)
Missing data 20 (17.7) 6 (17.1)
Metastatic disease at start of ADT (%)
Yes 71 (62.8) 22 (62.9)
No 42 (37.2) 13 (37.1)
PSA level at start of therapy (ng/mL)
Median 18.33 25.39
Interquartile range 5.1–83 3.03–71.14
without diabetes (HR for progression with diabetes= 1.19; 95%
CI: 0.77–1.89; p= 0.46; Figure 2A).
When patients were stratified based onwhether they had radio-
graphic evidence of metastatic disease at the onset of ADT, we
observed a greater difference in time to CRPC in the subset
of patients without radiographic evidence of metastatic disease
(N = 47; Figure 2B). In this subset of patients with a median
follow-up of 19.7months, 10 out of 11 (90.9%) patients with
diabetes progressed to CRPC, while 24 out of 36 (66.7%) of
patients without diabetes progressed to CRPC. The median time
to CRPCwas 9.4months for patients with diabetes compared with
36.4months for those without diabetes (HR for progression with
diabetes= 4.58; 95% CI: 1.92–10.94; p= 0.0006). There was no
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FIGURE 2 | Kaplan–Meier plot of time to CRPC from onset of ADT.
(A) Time to CRPC in all hormone-sensitive patients (N= 127). There was
no difference between patients with diabetes or without diabetes
(p= 0.46). (B) Time to CRPC in patients without radiographic evidence of
metastases (N= 47). Patients with diabetes in this subset were observed
to progress to CRPC significantly faster than patients without diabetes
(HR for progression with diabetes=4.58; 95% CI: 1.92–10.94;
p= 0.0006).
difference in time to CRPC between patients with and without
diabetes in the subgroup of patients who had metastatic disease
at the onset of ADT (HR= 0.65; 95% CI: 0.35–1.19; p= 0.16).
Overall Survival
In the same cohort of 127 patients who had undergone ADT for
hormone-sensitive PC, 6 out of 30 (20%) patients with concurrent
diabetes had died, and 34 out of 97 (35.1%) patients without
diabetes died. No statistically significant difference was seen inOS
from the time of ADT onset between patients with and without
diabetes. Median OS in patients with diabetes was 130.3months
compared with 76.7months in patients without diabetes (HR for
death with diabetes= 0.71; 95% CI: 0.29–1.63; p= 0.39).
In 108 patients with CRPC, 25 of whom had diabetes, there was
also no significant difference in OS from the date of CRPC diag-
nosis. Median follow-up after castration resistance was 23months
(range 0–127). Seven out of the 25 patients with diabetes died
(28%), and 34 out of the 83 patients without diabetes died (41%).
The median survival following the onset of CRPC in patients with
diabetes was 84.0months compared with 35.7months in patients
without diabetes (HR for death with diabetes= 0.57; 95% CI:
0.25–1.30; p= 0.184).
PSA Response Rate and Nadir PSA
A total of 92 patients who underwent ADT were evaluable for
PSA response. Patients without diabetes (N = 71) trended toward
a greater response rate than those without diabetes, though this
did not achieve statistical significance (84.5–71.4%; χ2= 1.84;
p= 0.17). Of 81 patients with CRPC with data available, there was
no observed difference in response rate based on a concurrent
diagnosis of diabetes (41.3–50%; p= 0.51).
A total of 103 patients were eligible for analysis of nadir PSA.
About 35.9% of patients without diabetes (N= 78) reached a
nadir PSA below 0.2 ng/mL compared with 16% of patients with
diabetes (N = 25), a trend that did not reach statistical significance
(χ2= 3.50; p= 0.061).
Discussion
There is a current dearth of literature examining the effects of dia-
betes on the progression of advanced PC.We tested the hypothesis
that a concurrent diagnosis of diabetes would lead to shorter time
to CRPC, shorter OS, and worse responses to therapies in patients
with PC. Though there was no difference in time to CRPC or OS
between patients with and without diabetes in the whole study
population, a subset analysis of patients without radiographic
evidence of metastases – presumably presenting with biochemical
recurrence – revealed a statistically significant difference in time
to CRPC between patients with and without diabetes, strongly
favoring patients without diabetes. In this study population, all
patients with metastases were observed to have a median time to
CRPC of 12.4months, which is consistent with the results from
the STAMPEDE trial (27). The effect of diabetes on time to CRPC
may have only been observed in patients without metastases at
the onset of ADT because these are patients who would otherwise
have the potential for a longer progression-free survival, whereas
those with metastases have disease that would progress more
quickly regardless of diabetic status.
Additionally, PC patients with diabetes were observed to have a
trend toward inferior PSA responses following ADT, though these
trends did not meet statistical significance. A lower percentage
of patients with diabetes experienced a 50% or greater reduction
from baseline PSA following ADT, and a lower percentage of
patients with diabetes reached a nadir PSA<0.2 ng/mL following
ADT, though neither of these observations reached statistical
significance. Higher PSA response rates and nadir PSA levels
<0.2 ng/mLhave each been associatedwith improved outcomes in
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patients with advanced PC (28–31). The fact that these indicators
trended toward worse outcomes in patients with diabetes was of
interest, since it followed the same directional pattern as time to
CRPC in non-metastatic PC.
Diabetes is associated with lower levels of testosterone, which is
one reason why the adverse effects of ADT include risk of diabetes
and hyperglycemia (32–35). With our findings, we speculate that
patients with long-standing diabetes might respond more poorly
to ADT since their cancers may have developed in the setting
of lower testosterone levels, possibly making their disease more
castration-resistant. Additionally, new onset diabetes secondary
to ADT can provide a mechanism for disease modification and
castration resistance, since new onset diabetes is associated with
hyperinsulinemia and insulin directly induces de novo steroido-
genesis in PC cells.
Apart from being a retrospective analysis, the largest limitation
of this study was its small sample size, particularly in the diabetic
cohort. Additionally, some of the patient data, such as Gleason
score at initial biopsy, disease burden at the start of treatment
and baseline PSA were unavailable, which lowered our sample
and limited our ability to account for potential disease-modifying
confounders. For instance, obesity has been shown to influence
PC progression in some populations, and is also associated with
higher insulin levels and lower testosterone levels (36, 37). Obe-
sity would therefore overlap with our proposed mechanisms for
disease progression conferred by diabetes. However, many of our
patients did not have data necessary to determine BMI. Addition-
ally, our median follow-up for patients from the onset of ADTwas
only 29months. Though this was enough follow-up to observe
a trend in time to CRPC, it may have been too short to make
definitive conclusions regarding survival.
Conclusion
These preliminary findings suggest there may be negative effects
of concurrent diabetes on progression of advanced PC. Further
efforts to fully describe these interactions should include inves-
tigation of larger databases for the relationship between dia-
betes and time to CRPC and OS in patients with advanced PC.
Additionally, the observation that the subset of patients without
metastases is particularly influenced by diabetes with a shorter
time to CRPC needs validation. The effects of glycemic control
and reducing endogenous insulin levels on the aforementioned
outcomes also require further examination, as targeting these
metabolic abnormalities may prove to be an important adjuvant
clinical intervention in these patients.
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